Glivec and Rash maculo-papular - a phase IV clinical study of FDA data

Summary:

Rash maculo-papular is reported as a side effect among people who take Glivec (imatinib mesylate), especially for people who are female, 2-9 old, have been taking the drug for 1 - 6 months also take Magnesium, and have Chronic myeloid leukaemia.

The phase IV clinical study analyzes which people have Rash maculo-papular when taking Glivec. It is created by eHealthMe based on reports of 17,769 people who have side effects when taking Glivec from the FDA, and is updated regularly.

What is Glivec?

Glivec has active ingredients of imatinib mesylate. eHealthMe is studying from 17,777 Glivec users. Check the latest studies of Glivec.

What is Rash maculo-papular?

Rash maculo-papular (red area on the skin that is covered with small confluent bumps) is found to be associated with 1,243 drugs and 1,534 conditions by eHealthMe. Check the latest studies of Rash maculo-papular.

On Jul, 20, 2026

17,769 people reported to have side effects when taking Glivec.
Among them, 29 people (0.16%) have Rash maculo-papular.

Among these 29 people:

How long have people been on Glivec when they have Rash maculo-papular? *

What is the gender of people who have Rash maculo-papular when taking Glivec? *

female: 51.72 %
male: 48.28 %

What is the age of people who have Rash maculo-papular when taking Glivec? *

What are other drugs people take besides Glivec? *

What are other side effects people have besides Rash maculo-papular? *

Hypersensitivity: 11 people, 37.93%
Nausea (feeling of having an urge to vomit): 10 people, 34.48%
Itching: 10 people, 34.48%
Diarrhea: 9 people, 31.03%
Anaemia (lack of blood): 9 people, 31.03%
Weakness: 8 people, 27.59%
Abdominal Pain: 7 people, 24.14%
Thrombocytopenia (decrease of platelets in blood): 7 people, 24.14%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 7 people, 24.14%
White Blood Cell Count Decreased: 6 people, 20.69%

What are the existing conditions these people have? *

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 12 people, 41.38%
Gastrointestinal Stromal Tumor: 6 people, 20.69%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 6 people, 20.69%
High Blood Pressure: 5 people, 17.24%
Venous Occlusion (the blocking of venous return): 4 people, 13.79%
Myeloid Leukaemia (a type of cancer in which the bone marrow makes abnormal myeloblasts): 4 people, 13.79%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 4 people, 13.79%
Thrombocytopenia (decrease of platelets in blood): 3 people, 10.34%
Stress And Anxiety: 1 person, 3.45%
Onchocerciasis (a parasitic disease caused by the filarial worm): 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Glivec and have Rash maculo-papular?

- Check whether Rash maculo-papular is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Glivec:

Glivec (17,777 reports)

Browse all side effects of Glivec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rash maculo-papular:

Rash maculo-papular (1,243 drugs)

Browse all the conditions that are associated with Rash maculo-papular:

Rash maculo-papular (1,534 conditions)

Related publications that referenced our studies

O'rafferty C, McElligott F, Storey L, O'marcaigh A, Smith O, "Pneumatosis intestinalis and imatinib mesylate", Annals of hematology, 2014 Oct .
O'rafferty C, McElligott F, Storey L, O'marcaigh A, Smith O, "Pneumatosis intestinalis and imatinib mesylate", Annals of hematology, 2014 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on imatinib mesylate (the active ingredients of Glivec) and Glivec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.